2025年4月5日 周六
Home > Archive>Volume 26, Issue 2, 2018 >194-200
PDF HTML XML Export Cite reminder
Research progress of lipoprotein(a)
CSTR:
[cstr]
Author:
Affiliation:

a) QIN Qun-Ting, DENG Xiu-Ting, LU Wen-Sheng (Department of Endocrinology, the People's Hospital of Guangxi Zhuang Autonomous Region, Nanning 530021, Guangxi, China)

Clc Number:

R587.1

  • Article
    • | |
  • Metrics
    • |
  • Reference [59]
    • |
  • Related [20]
    • | | |
  • Comments
    Abstract:

    Lipoprotein(a) is a high risk factor for the formation and progression of atherosclerosis, and high level of lipoprotein(a) has been confirmed as a predictor of coronary heart disease. Because it is mainly controlled by genetics, diet, exercise, lifestyle, traditional lipid-lowering drugs have little effect on lipoprotein(a) level. With the deepening research, the metabolism, pathogenesis and harm of lipoprotein(a) have been gradually understood. Oxidized modified lipoprotein(a) has a stronger atherogenic effect. New lipid lowering drugs that reduce lipoprotein(a) have been developed, each of them has different target, functional intensity and mechanism of action on lowering lipoprotein(a), and the effect on the prognosis of the disease remains to be observed. This paper reviews the research progress of lipoprotein(a) metabolism, genetic regulation, oxidative modification and clinical intervention.

    Reference
    [1] Berg K.A new serum type system in man--the Lipoprotein system.Acta Pathol Microbiol Scand, 3,9:369-382.
    [2] Tregouet DA, Konig IR, Erdmann J, et al.Genome-wide haplotype association study identifies the SLC22A3-LPAL2-LPA gene cluster as a risk locus for coronary artery disease.Nat Genet, 9,1(3):283-285.
    [3] Ober C, Abney M, Mcpeek MS.The genetic dissection of complex traits in a founder population.Am J Hum Genet, 1,9(5):1 068-079.
    [4] Rainwater DL, Kammerer CM, Vandeberg JL, et al.Characterization of the genetic elements controlling lipoprotein(a) concentrations in Mexican Americans:Evidence for at least three controlling elements linked to LPA, the locus encoding apolipoprotein(a).Atherosclerosis, 7,8(2):223-233.
    [5] Kronenberg F, Utermann G.Lipoprotein(a):resurrected by genetics.J Intern Med, 3,3(1):6-30.
    [6] Lu W, Cheng YC, Chen K, et al.Evidence for several independent genetic variants affecting lipoprotein(a) cholesterol levels.Hum Mol Genet, 5,4(8):2 390-400.
    [7] Nassir F, Bonen DK, Davidson NO.Apolipoprotein(a) synthesis and secretion from hepatoma cells is coupled to triglyceride synthesis and secretion.J Biol Chem, 8,3(28):17 793-800.
    [8] Tsimikas S.A test in context--Lipoprotein(a):diagnosis, prognosis, controversies, and emerging therapies.J Am Coll Cardiol, 7,9(6):692-711.
    [9] Khera AV, Everett BM, Caulfield MP, et al.Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk:an analysis from the JUPITER trial (Justification for the use of statins in prevention:an intervention trial evaluating rosuvastatin).Circulation, 4,9(6):635-642.
    [10] Lamon-Fava S, Diffenderfer MR, Marcovina SM.Lipoprotein(a) metabolism.Curr Opin Lipidol, 4,5(3):189-193.
    [11] Diffenderfer MR, Lamon-Fava S, Marcovina SM, et al.Distinct metabolism of apolipoprotein A and B100 within plasma lipoprotein(a).Metabolism, 6,5(4):381-390.
    [12] Jacobson TA.Lipoprotein(a), cardiovascular disease, and contemporary management.Mayo Clin Proc, 3,8(11):1 294-311.
    [13] Frischmann ME, Kronenberg F, Trenkwalder E, et al.In vivo turnover study demonstrates diminished clearance of lipoprotein(a) in hemodialysis patients.Kidney Int, 7,1(10):1 036-043.
    [14] Ikewaki K.In vivo kinetic studies to further understand pathogenesis of abnormal lipoprotein metabolism in chronic kidney disease.Clin Exp Nephrol, 4,8(2):261-264.
    [15] Yang XP, Amar MJ, Vaisman B, et al.Scavenger receptor-B1 is a receptor for lipoprotein(a).J Lipid Res, 3,4(9):2 450-457.
    [16] Schmidt K, Noureen A, Kronenberg F, et al.Thematic review series--Lipoprotein(a):coming of age at last structure, function, and genetics of lipoprotein(a).J Lipid Res, 6,7(8):1 339-359.
    [17] Spence JD, Koschinsky M.Mechanisms of lipoprotein(a) pathogenicity:prothrombotic, proatherosclerotic, or both?.Arterioscler Thromb Vasc Biol, 2,2(7):1 550-551.
    [18] Leibundgut G, Scipione C, Yin H, et al.Determinants of binding of oxidized phospholipids on apolipoprotein A and lipoprotein(a).J Lipid Res, 3,4(10):2 815-830.
    [19] Buechler C, Ullrich H, Ritter M, et al.Lipoprotein(a) up-regulates the expression of the plasminogen activator inhibitor 2 in human blood monocytes.Blood, 1,7(4):981-986.
    [20] van der Valk FM, Bekkering S, Kroon J, et al.Oxidized phospholipids on lipoprotein(a) elicit arterial wall inflammation and an inflammatory monocyte response in humans.Circulation, 6,4(8):611-624.
    [21] Koschinsky ML, Marcovina SM.Structure-function relationships in apolipoprotein A:insights into lipoprotein(a) assembly and pathogenicity.Curr Opin Lipidol, 4,5(2):167-174.
    [22] Erqou S, Kaptoge S, Perry PL, et al.Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality.J Am Med Assoc, 9,2(4):412-423.
    [23] Kamstrup PR, Tybjaerg-Hansen A, Nordestgaard BG.Extreme lipoprotein(a) levels and improved cardiovascular risk prediction.J Am Coll Cardiol, 3,1(11):1 146-156.
    [24] Clarke R, Peden JF, Hopewell JC, et al.Genetic variants associated with Lp(a) lipoprotein level and coronary disease.N Engl J Med, 9,1(26):2 518-528.
    [25] Shiffman D, Louie JZ, Rowland CM, et al.Single variants can explain the association between coronary heart disease and haplotypes in the apolipoprotein A locus.Atherosclerosis, 0,2(1):193-196.
    [26] Koch W, Mueller JC, Schrempf M, et al.Two rare variants explain association with acute myocardial infarction in an extended genomic region including the apolipoprotein A gene.Ann Hum Genet, 3,7(1):47-55.
    [27] Helgadottir A, Gretarsdottir S, Thorleifsson G, et al.Apolipoprotein A genetic sequence variants associated with systemic atherosclerosis and coronary atherosclerotic burden but not with venous thromboembolism.J Am Coll Cardiol, 2,0(8):722-729.
    [28] Yeang C, Wilkinson MJ, Tsimikas S.Lipoprotein(a) and oxidized phospholipids in calcific aortic valve stenosis.Curr Opin Cardiol, 6,1(4):440-450.
    [29] Vongpromek R, Bos S, Ten KG, et al.Lipoprotein(a) levels are associated with aortic valve calcification in asymptomatic patients with familial hypercholesterolaemia.J Intern Med, 5,8(2):166-173.
    [30] Kamstrup PR, Tybjaerg-Hansen A, Nordestgaard BG.Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population.J Am Coll Cardiol, 4,3(5):470-477.
    [31] Arsenault BJ, Boekholdt SM, Dube MP, et al.Lipoprotein(a) levels, genotype, and incident aortic valve stenosis:a prospective Mendelian randomization study and replication in a case-control cohort.Circ Cardiovasc Genet, 4,7(3):304-310.
    [32] Chan KL, Teo K, Dumesnil JG, et al.Effect of Lipid lowering with rosuvastatin on progression of aortic stenosis:results of the aortic stenosis progression observation:measuring effects of rosuvastatin (ASTRONOMER) trial.Circulation, 0,1(2):306-314.
    [33] Alonso R, Andres E, Mata N, et al.Lipoprotein(a) levels in familial hypercholesterolemia:an important predictor of cardiovascular disease independent of the type of LDL receptor mutation.J Am Coll Cardiol, 4,3(19):1 982-989.
    [34] Alonso R, Mata P, Zambon D, et al.Early diagnosis and treatment of familial hypercholesterolemia:improving patient outcomes.Expert Rev Cardiovasc Ther, 3,1(3):327-342.
    [35] Marzano L, Colussi G, Del Torre M, et al.Relationships of plasma lipoprotein(a) levels with insulin resistance in hypertensive patients.Metabolism, 4,3(11):1 439-446.
    [36] 芦波, 刘莉.脂蛋白(a)与代谢综合征组分的相关性研究.中国热带医学, 5,5(8):970-973.
    [37] Bozbas H, Yildirir A, Pirat B, et al.Increased lipoprotein(a) in metabolic syndrome:is it a contributing factor to premature atherosclerosis?.Anadolu Kardiyol Derg, 8,8(2):111-115.
    [38] Edelstein C, Pfaffinger D, Hinman J, et al.Lysine-phosphatidylcholine adducts in kringle V impart unique immunological and potential pro-inflammatory properties to human apolipoprotein A.J Biol Chem, 3,8(52):52 841-847.
    [39] Hoover-Plow J, Huang M.Lipoprotein(a) metabolism:Potential sites for therapeutic targets.Metabolism, 3,2(4):479-491.
    [40] Wang J, Niu D, Meng Y, et al.Plasma oxidized lipoprotein(a) and its immune complexes are present in newborns and children.Clin Chim Acta, 9,7(1-2):1-5.
    [41] Wang J, Hu B, Kong L, et al.Native, oxidized lipoprotein(a) and lipoprotein(a) immune complex in patients with active and inactive rheumatoid arthritis:plasma concentrations and relationship to inflammation.Clin Chim Acta, 8,0(1-2):67-71.
    [42] 韩爱忠, 汪俊军.脂蛋白(a)与心血管疾病的关系.临床心血管病杂志, 2,8(9):643-645.
    [43] 程京华, 宫剑滨.冠心病患者冠状动脉介入术前后血清氧化脂蛋白(a)水平变化.中华实用诊断与治疗杂志, 4,8(3):227-228.
    [44] 朱铁兵, 杨志健, 王连生, 等.氧化型脂蛋白(a)对人脐静脉内皮细胞表达巨噬细胞炎性蛋白1α的影响.中国动脉硬化杂志, 4,2(5):556-558.
    [45] Parhofer KG.Interaction between glucose and lipid metabolism:More than diabetic dyslipidemia.Diabetes Metab J, 5,9(5):353-362.
    [46] Barter PJ, Rye KA.New era of Lipid-lowering drugs.Pharmacol Rev, 6,8(2):458-475.
    [47] Tsimikas S, Viney NJ, Hughes SG, et al.Antisense therapy targeting apolipoprotein A:a randomised, double-blind, placebo-controlled phase 1 study.Lancet, 5,6(10002):1 472-483.
    [48] Crooke ST, Geary RS.Clinical pharmacological properties of mipomersen (Kynamro), a second generation antisense inhibitor of apolipoprotein B.Br J Clin Pharmacol, 3,6(2):269-276.
    [49] Lagace TA, Curtis DE, Garuti R, et al.Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice.J Clin Invest, 6,6(11):2 995-3 005.
    [50] 李红艳.冠心病患者PCSK9和脂蛋白(a)水平与冠状动脉病变程度的相关性.中国动脉硬化杂志, 6,4(6):607-610.
    [51] Tavori H, Christian D, Minnier J, et al.PCSK9 association with lipoprotein(a).Circ Res, 6,9(1):29-35.
    [52] Raal F, Scott R, Somaratne R, et al.Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia:the reduction of LDLC with PCSK9 inhibition in heterozygous familial hypercholesterolemia disorder (RUTHERFORD) randomized trial.Circulation, 2,6(20):2 408-417.
    [53] Desai NR, Giugliano RP, Zhou J, et al.AMG 145, a monoclonal antibody against PCSK9, facilitates achievement of national cholesterol education program-adult treatment panel III low-density lipoprotein cholesterol goals among high-risk patients:an analysis from the LAPLACE-TIMI 57 trial (LDLC assessment with PCSK9 monoclonal antibody inhibition combined with statin therapy-thrombolysis in myocardial infarction 57).J Am Coll Cardiol, 4,3(5):430-433.
    [54] Koren MJ, Lundqvist P, Bolognese M, et al.Anti-PCSK9 monotherapy for hypercholesterolemia:the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab.J Am Coll Cardiol, 4,3(23):2 531-540.
    [55] Chen F, Maccubbin D, Yan L, et al.Lipid-altering efficacy and safety profile of co-administered extended release niacin/laropiprant and simvastatin versus atorvastatin in patients with mixed hyperlipidemia.Int J Cardiol, 3,7(1):225-231.
    [56] Ganji SH, Kamanna VS, Kashyap ML.Niacin and cholesterol:role in cardiovascular disease (review).J Nutr Biochem, 3,4(6):298-305.
    [57] Akaike M, Azuma H, Kagawa A, et al.Effect of aspirin treatment on serum concentrations of lipoprotein(a) in patients with atherosclerotic diseases.Clin Chem, 2,8(9):1 454-459.
    [58] Li Y, Luke MM, Shiffman D, et al.Genetic variants in the apolipoprotein A gene and coronary heart disease.Circ Cardiovasc Genet, 1,4(5):565-573.
    [59] Emdin CA, Khera AV, Natarajan P, et al.Phenotypic characterization of genetically lowered human lipoprotein(a) levels.J Am Coll Cardiol, 6,8(25):2 761-772.
    Cited by
    Comments
    Comments
    分享到微博
    Submit
Get Citation

QIN Qun-Ting, DENG Xiu-Ting, LU Wen-Sheng. Research progress of lipoprotein(a)[J]. Editorial Office of Chinese Journal of Arteriosclerosis,2018,26(2):194-200.

Copy
Share
Article Metrics
  • Abstract:1441
  • PDF: 954
  • HTML: 0
  • Cited by: 0
History
  • Received:March 27,2017
  • Revised:May 01,2017
  • Online: March 07,2018
Article QR Code

You are the 27904 visitor

Post Code：421001 Fax：0734-8160523

Phone：0734-8160765 E-mail：dmzzbjb@163.net

Editorial Office of Chinese Journal of Arteriosclerosis ® 2025